• Current position:
Bb-Dar™ Platform:
Antibody Designed for Site-specific Conjugation
where ADC lead molecules contain desired DARs (DAR = 2, 4, 6, 8 or 10)
Bispecific or tri-specific ADC for multi-functionality
BliST™:
Multi-target fusion protein
BliSC™:
Multi-cleavage mechanism linker
Proprietary linker to have Enzymatic cleavage of linker-payload by dual mechanism to overcome toxicity issues
BliSD™:
Multi-mechanism payloads
Proprietary technology to contain dual mechanism toxins with the desired ratio
Drug
Target
Discovery
Lead
Optimization
IND-
Enabling
Phase I
Phase II
Phase III
BB-1701
HER2
BB-1705
EGFR
BB-1709
CD73
BB-1712
B7H3
BB-1710
-
BB-1708
BR**